Coronavirus disease 2019 (COVID‐19) caused by a novel coronavirus called severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is driving a present day global pandemic. Immunosuppressed patients are regarded as a high‐risk cohort. The following is a short report on COVID‐19 in liver transplant recipients (n = 5) from a high volume UK liver transplant unit with a large follow‐up cohort (n = 4500). Based on this limited data, liver transplant recipients appear to have a low incidence of COVID‐19, with less severe symptoms than expected, when compared with the general population and other solid organ recipients. This possibly could be related to self‐isolation adherence and/or the ‘ideal’ level of immunosuppression that favourably modulates the immune response to COVID‐19.

中文翻译：

---

肝移植后受者中 COVID-19 的低患病率和疾病严重程度——单中心经验。

由一种称为严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 的新型冠状病毒引起的 2019 年冠状病毒病 (COVID-19) 正在推动当今的全球大流行。免疫抑制患者被视为高危人群。以下是一份关于肝移植受者（n = 5）中 COVID-19 的简短报告，来自一个大容量的英国肝移植单位和一个大型随访队列（n = 4500）。基于这些有限的数据，与普通人群和其他实体器官受者相比，肝移植受者的 COVID-19 发病率似乎较低，症状比预期的要轻。这可能与自我隔离依从性和/或有利于调节对 COVID-19 的免疫反应的“理想”免疫抑制水平有关。